PYC Therapeutics Advances in Genetic Eye Disorder Treatment with PYC-001 Study

PYC Therapeutics Limited ((AU:PYC)) announced an update on their ongoing clinical study.

Study Overview: PYC Therapeutics Limited is conducting a Phase 1a open-label study titled ‘SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)’. The study aims to evaluate the safety and tolerability of PYC-001, a potential treatment for individuals with confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA), a hereditary eye condition that leads to vision loss.

Intervention/Treatment: The study is testing PYC-001, a drug administered intravitreally, designed to address the genetic mutation causing ADOA. The intervention focuses on determining the drug’s safety profile in human subjects.

Study Design: This is an interventional study with a single-group assignment. Participants receive ascending doses of PYC-001 in an open-label format, meaning both researchers and participants know the treatment being administered. The primary goal is treatment-focused, specifically assessing safety and tolerability.

Study Timeline: The study began on June 5, 2024, with the latest update submitted on July 29, 2025. These dates mark the study’s progression and ongoing recruitment efforts, crucial for tracking its development and future milestones.

Market Implications: The ongoing study of PYC-001 could significantly impact PYC Therapeutics’ stock performance, especially if safety and tolerability results are positive. Success in this trial could position PYC-001 as a leading treatment for ADOA, potentially affecting investor sentiment and placing PYC Therapeutics ahead of competitors in the genetic eye disorder treatment space.

The study is currently recruiting, with further details available on the ClinicalTrials portal.